HIV-1 p24 Antibody Cat. No.: 7313

Availability: In stock

$0.00

 Price Options

* Required Fields

$0.00
psi-iconSpecifications
HOST SPECIES:Rabbit
SPECIES REACTIVITY: Virus
IMMUNOGEN: Rabbit polyclonal HIV-1 p24 antibody was raised against a recombinant full-length HIV-1 p24 protein .
TESTED APPLICATIONS: ELISA, WB
APPLICATIONS: P24 antibody can be used for detection of p24 by Western blot at 0.5 - 1 μg/mL.
SPECIFICITY: P24 antibody detects a 24 kDa recombinant protein.
POSITIVE CONTROL:1) Cat. No. 95-153 - HIV-1 p24 Recombinant Protein
PREDICTED MOLECULAR WEIGHT: 24 kDa

psi-iconProperties
PURIFICATION:HIV-1 p24 Antibody is affinity chromatography purified via peptide column.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:HIV-1 p24 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:HIV-1 p24 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

psi-iconAdditional Info
OFFICIAL SYMBOL:GAG
ALTERNATE NAMES:HIV-1 p24 Antibody: Gag polyprotein, Pr55Gag, MA
ACCESSION NO.:AAB50258
PROTEIN GI NO.:327745
GENE ID:155030
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.
REFERENCES:1) Goto T, Nakai M, and Ikuta K. The life-cycle of human immunodeficiency virus type 1. Micron 1998; 29:123-38.
2) Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251:1-15.
3) Lindenburg CE, Stolte I, Langendam MW, et al. Long-term follow-up : no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002 ; 20 :2343-7.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.